Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Artivila Biopharma currently faces 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 2 distinct examiners and 2 distinct art units. This shows that the company's current pending workload is split between different examiners, providing a small degree of diversification in the prosecution process. The presence of 2 distinct art units suggests that the pending applications cover different technical sub-specialties within the biotechnology sector.
SZNAIDMAN, MARCOS L is designated as the busiest examiner for the portfolio. This examiner is currently managing 1 pending office action for the company, while the other pending matter is handled by a different examiner. Because the 2 pending office actions are spread across 2 distinct examiners, the company must navigate the specific preferences and requirements of multiple individuals. This distribution can lead to varying timelines for the resolution of the pending office actions, as each examiner and art unit may have different average processing speeds and examination styles.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZNAIDMAN, MARCOS L | 1 | 37.4% | +16.1% |
| SCHMIDT, IZABELA MARIA | 1 | 65.7% | +42.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18036673 | SARM1 ENZYME ACTIVITY INHIBITOR AND USE THEREOF IN NEURODEGENERATIVE DISEASES | SCHMIDT, IZABELA MARIA | 30d |
| 18723903 | Polymyxin Antibiotic Synergist and Anti-Gram-Negative Bacteria Pharmaceutical Composition | SZNAIDMAN, MARCOS L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18036673 | SARM1 ENZYME ACTIVITY INHIBITOR AND USE THEREOF IN NEURODEGENERATIVE DISEASES | SCHMIDT, IZABELA MARIA | 30d |
| 18723903 | Polymyxin Antibiotic Synergist and Anti-Gram-Negative Bacteria Pharmaceutical Composition | SZNAIDMAN, MARCOS L | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18723903 | Polymyxin Antibiotic Synergist and Anti-Gram-Negative Bacteria Pharmaceutical Composition | SZNAIDMAN, MARCOS L | 1628 | §102§103 | Non-Final OA | — | Pending | Jun 25, 2024 |
| 18036673 | SARM1 ENZYME ACTIVITY INHIBITOR AND USE THEREOF IN NEURODEGENERATIVE DISEASES | SCHMIDT, IZABELA MARIA | 1621 | §102§103 | Final Rejection | 30d | Pending | May 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialArtivila Biopharma has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Marcos L Sznaidman has the most, with 1 of Artivila Biopharma's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
